Radiolabeled bevacizumab (National Cancer Institute/University Hospital Groningen)

N/A

Report date: 2025/09/09 15:00:23

Base Information

Drug NameRadiolabeled bevacizumab (National Cancer Institute/University Hospital Groningen)
Drug Alias Name89Zr-N-sucDf-bevacizumab89Zr radiolabeled bevacizumabZirconium-89-bevacizumabBevacizumab-[89Zr]89Zr-bevacizumab +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Zirconium > 89Zr +[5] 
Mechanisms of ActionVascular endothelial growth factor modulators
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiagnostic agentsInflammatory Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteUniversity Hospital Groningen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteUniversity Hospital GroningenNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsDiagnostic agentsInflammatory Breast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A